Bromocriptine and Acromegaly: Therapeutic Implications
نویسندگان
چکیده
منابع مشابه
Bromocriptine-induced psychosis in acromegaly.
Dopaminergic mechanisms have been implicated in the pathogenesis of schizophrenia.' Psychosis induced by the dopamine-receptor agonist bromocriptine has been described mainly with high-dose regimens in Parkinsonism and less frequently with the lower doses used in hormonal disorders.24 The following case is of interest because of the insidious onset of psychosis and the family history of paranoi...
متن کاملPrediction of response to bromocriptine in acromegaly.
BROMOCRIPTINE was first used in the treatment of acromegaly in 1974 (Liuzzi et al, 1974 a). Not all patients show lowered human growth hormone in response to the drug (Liuzzi et al, 1974 a; Thorner and Besser, 1975; Sachdev et al, 1975). We have performed a series of tests on acromegalic patients in an attempt to discover if any test could predict those patients likely to show !ong-term respons...
متن کاملThe Combination Therapy with Bromocriptine and Cyproheptadine in Patients with Acromegaly
The therapeutic efficacy of the combination of cyproheptadine and bromocriptine was studied in 15 patients with active acromegaly showing incomplete GH suppression in response to bromocriptine therapy alone. The mean basal plasma GH was 31.3±5.5 µg/L, and it decreased to 19.0±3.9 µg/L during the single bromocriptine therapy (10-20 mg for 2 to 21 months). When cyproheptadine (12 to 16 mg for 8 t...
متن کاملGrowth hormone responses to hp GRF 1-44 amide, bromocriptine and stress in acromegaly are correlated.
The results of testing growth hormone (GH) reserve using human pancreatic growth hormone-releasing factor 1-44 amide (hp GRF 1-44 amide) have been compared with the GH responses in a variety of other dynamic tests in seven acromegalic patients. The GH release following hp GRF 1-44 amide correlated with the GH suppression following bromocriptine, but showed an inverse correlation with the GH rel...
متن کاملBromocriptine, a dopamine agonist, increases growth hormone secretion in a patient with acromegaly.
Bromocriptine, a potent D2-dopamine agonist, suppresses growth hormone (GH) secretion in most patients with acromegaly and has been approved for the treatment of acromegaly. Here we report a patient with acromegaly who showed increased GH secretion after administration of bromocriptine. A 70-year-old man with acromegalic manifestation was admitted to our hospital because of a pituitary tumor in...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the Royal Society of Medicine
سال: 1979
ISSN: 0141-0768,1758-1095
DOI: 10.1177/014107687907200804